MediPharm Labs Corp.

As of June 30, 2026, MediPharm Labs Corp. carries a market capitalization of 29.90M, placing it among publicly traded companies globally. Its enterprise value stands at 20.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MediPharm Labs Corp.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, MediPharm Labs Corp. has 427.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.72, and the price-to-book ratio stands at 0.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 20.47M versus a market cap of 29.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MediPharm Labs Corp. maintains a current ratio of 2.69, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.19, indicating moderate leverage, while an interest coverage ratio of -57.40 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MediPharm Labs Corp. posted a negative return on equity (ROE) of -13.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.44, reflecting losses generated across the asset base. The company generates approximately 305,955.72 in revenue per employee across its workforce of 135.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.86 indicates how many times MediPharm Labs Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, MediPharm Labs Corp.'s stock has declined approximately 13.33% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.07.

Over the twelve months ended June 30, 2026, MediPharm Labs Corp. generated 41.46M in revenue and converted that into -4.97M in net income, yielding earnings per share of -0.01. EBITDA reached -3.56M, while operating income came in at -5.11M.

As of June 30, 2026, MediPharm Labs Corp. holds 9.85M in cash and equivalents against 421,000.00 in total debt, resulting in a net debt position of -9.44M. Total book value stands at 35.43M, with working capital of 17.88M providing operational flexibility.

MediPharm Labs Corp. produced -981,000.00 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, MediPharm Labs Corp. posted a gross margin of 33.99, reflecting its pricing power and cost economics. The operating margin of -12.33 and net profit margin of -12.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, MediPharm Labs Corp. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.16, meaning MediPharm Labs Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MediPharm Labs Corp.'s most recent stock split took place on October 4, 2018 with a 2:1 split ratio.

As of June 30, 2026, MediPharm Labs Corp. has an Altman Z-Score of -2.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.